Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers

Background Accurate clinical staging is crucial to managing gastrointestinal cancer, but fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT has limitations. Targeting fibroblast-activation protein a newer diagnostic approach for the visualization of tumor stroma, and gallium 68 (68Ga)-labeled inhibitors (FAPIs), hereafter 68Ga-FAPIs, present promising alternative 18F-FDG. Purpose To compare efficacy 68Ga-FAPI in primary metastatic lesions malignancies with that 18F-FDG PET/CT. Materials Methods Images from patients gastric, duodenal, colorectal cancers who underwent contemporaneous between October 2019 through June 2020 were retrospectively analyzed. uptakes compared by using Wilcoxon signed-rank test. The McNemar test was used performance two techniques. Results Thirty-five (median age, 64 years [interquartile range, 53-68 years]; men) evaluated. In treatment-naive (n = 19), led upstaging TNM stage four (21%) Tracer uptake higher than (gastric cancer: 12.7 vs 3.7, respectively, P .003; 15.9 7.9, .03), involved lymph nodes (6.7 2.4, < .001), bone visceral metastases (liver metastases: 9.7 5.2, .001; peritoneal 8.4 3.6, 4.3 2.2, lung 4.4 1.9, .01). addition, sensitivity detection tumors (100% [19 19] 53% [10 19], respectively; .004), (79% [22 28] 54% [15 28], (89% [31 35] 57% [20 35], .001). Conclusion Gallium inhibitor superior cancers, tracer most lesions. Published under CC BY 4.0 license.